Using a Modified ALCL99 Regimen for Chinese Children with Newly Diagnosed High-risk Anapestic Large Cell Lymphoma
Who is this study for? Chinese children with newly diagnosed high-risk anapestic large cell lymphoma
What treatments are being studied? Modified ALCL99 Regimen
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
A prospective study on the efficacy of modified ALCL99 regimens in the treatment of the current Chinese pediatric and adolescent high-risk ALCL and compared with our historical data.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
Healthy Volunteers: f
View:
• Patient must be ≤ 18 years at the time of diagnosis
• Newly diagnosed patients with histologically confirmed high-risk anaplastic large cell lymphoma
• No congenital immunodeficiency, HIV infection, or prior organ transplant
Locations
Other Locations
China
Shanghai Children's Medical Center
RECRUITING
Shanghai
Contact Information
Primary
Qing Yuan, MD
1832975884@qq.com
+8613062865879
Backup
Yali Han, MD
hanyali@scmc.com.cn
+8613661574996
Time Frame
Start Date: 2021-03-01
Estimated Completion Date: 2029-03-01
Participants
Target number of participants: 172
Treatments
Experimental: High risk group
1. Stage I, unresected; Stage I with B syndrome~2. Stage II~3. Stage III~4. Stage IV without CNS involvement
Related Therapeutic Areas
Sponsors
Collaborators: 1st Affiliated Hospital of Zhengzhou University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Qilu Hospital of Shandong University, Tianjin Cancer Hospital, Xiangya Hospital, Nanjing Children's Hospital, Shanghai Children's Medical Center, Shenzhen Children's Hospital, West China Second University Hospital
Leads: Children's Cancer Group, China